BB Biotech AG

BB Biotech reported CHF 451 million net profit in Q2 2026, reversing a CHF 100 million loss from Q2 2025. NAV delivered a 17.2% total return in CHF, outpacing the Nasdaq Biotechnology Index by 3.5 per